Note 3 - Balance Sheet Components

12 Months Ended

Dec. 31, 2025

Notes to Financial Statements

Supplemental Balance Sheet Disclosures [Text Block]

3.         Balance Sheet Components

Prepaid expenses and other current assets consist of the following as of December 31, 2025 and 2024:

	2025		2024
Prepaid clinical trial costs	$	1,197,679	$	1,524,813
Prepaid insurance premiums		165,067		220,675
Prepaid rent		16,000		13,045
Prepaid contract manufacturing costs		783,321		-
Other		66,843		10,000
Total prepaid expenses	$	2,228,910	$	1,768,533

Property and equipment consist of the following as of December 31, 2025 and 2024:

	2025			2024
Equipment and furnishings	$	512,437		$	795,411
Leasehold improvements		-			115,605
Total property and equipment		512,437			911,016
Accumulated depreciation and amortization		(403,607	)		(761,042	)
Total property and equipment, net	$	108,830		$	149,974

Depreciation expense was $68,756 and $80,368 during the years ended December 31, 2025 and 2024, respectively.

Other assets consist of the following as of December 31, 2025 and 2024:

	2025		2024
Prepaid technology license fees	$	50,000	$	60,000
Deposits		36,947		11,010
Total other assets	$	86,947	$	71,010

Accrued expenses consist of the following as of December 31, 2025 and 2024:

	2025		2024
Payroll-related liabilities	$	181,584	$	986,691
Accrued clinical trial costs		587,303		200,881
Other accrued expenses		113,929		70,000
Total accrued expenses	$	882,816	$	1,257,572